Medication-related osteonecrosis of the jaw (MRONJ)
Bisphosphonate/antiresorptive jaw necrosis · Dental & Oral
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Exposed, non-healing jaw bone (>8 weeks) in a patient on antiresorptive (bisphosphonates, denosumab) or antiangiogenic drugs, with no history of head and neck radiotherapy. Often precipitated by dental extraction; higher risk with IV bisphosphonates/denosumab for malignancy.
Red flags
- Pathological fracture or orocutaneous fistula
- Spreading infection / systemic sepsis
- Suspected malignancy
- Rapid progression of exposed bone
Assessment
Differential diagnosis
- Osteoradionecrosis
- Chronic osteomyelitis
- Metastatic/primary jaw malignancy
- Dental abscess / alveolar osteitis
- Periodontal disease
- Odontogenic infection
Investigations
- Drug history — bisphosphonates, denosumab, antiangiogenics; route and duration
- Confirm no prior head/neck radiotherapy
- Oral exam — exposed/necrotic bone or probeable fistula >8 weeks
- OPG / CT to assess extent and pathological fracture
- Exclude metastasis/malignancy
- Bloods if systemic infection suspected
Management
- Confirm diagnosis and stage (asymptomatic exposed bone vs infection vs fracture/fistula)
- Optimise oral hygiene with antiseptic mouthwash
- Treat secondary infection with antibiotics and analgesia as needed
- Avoid unnecessary surgery/extractions in affected bone; conservative care for early disease
- Refer to OMFS for staging and management (sequestrectomy/resection for advanced disease)
- Liaise with the prescribing team about drug holiday for malignancy indications (individualised)
- Reinforce prevention: dental assessment and treatment BEFORE starting antiresorptives
- Safety-net for progression, fracture or spreading infection
Drugs & doses
Chlorhexidine 0.2% mouthwash — 10 mL BD — antiseptic rinse
Amoxicillin — 500 mg PO TDS (+ metronidazole 400 mg PO TDS) — secondary infection
Doxycycline — 100 mg PO OD — penicillin-allergic alternative
Paracetamol +/- opioid — analgesia titrated to pain
Disposition
Refer to OMFS for staging and conservative/surgical management; treat infection and pain; coordinate with the prescribing team and emphasise prevention.
Complications & pitfalls
- Chronic pain and infection
- Pathological fracture
- Fistula formation
- Extensive bone loss requiring resection
- Impaired nutrition
Exam pearls
- Risk is much higher with IV bisphosphonates/denosumab for cancer than oral bisphosphonates for osteoporosis
- Prevention is paramount — complete invasive dental work before starting antiresorptive therapy
- Do not stop antiresorptives without discussion with the prescriber; drug holidays are individualised
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.